Plague-Pipeline Review, H2 2015

Plague-Pipeline Review, H2 2015


  • Products Id :- GMDHC6988IDB
  • |
  • Pages: 62
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Plague-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Plague-Pipeline Review, H2 2015', provides an overview of the Plague's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Plague, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Plague and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Plague

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Plague and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Plague products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Plague pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Plague

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Plague pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Plague Overview 7

Therapeutics Development 8

Pipeline Products for Plague-Overview 8

Pipeline Products for Plague-Comparative Analysis 9

Plague-Therapeutics under Development by Companies 10

Plague-Therapeutics under Investigation by Universities/Institutes 11

Plague-Pipeline Products Glance 12

Clinical Stage Products 12

Early Stage Products 13

Unknown Stage Products 14

Plague-Products under Development by Companies 15

Plague-Products under Investigation by Universities/Institutes 16

Plague-Companies Involved in Therapeutics Development 17

Aradigm Corporation 17

Grifols, S.A. 18

iBio, Inc. 19

Mucosis B.V. 20

Syntiron LLC 21

Tetraphase Pharmaceuticals Inc. 22

Plague-Therapeutics Assessment 23

Assessment by Monotherapy Products 23

Assessment by Combination Products 24

Assessment by Target 25

Assessment by Mechanism of Action 27

Assessment by Route of Administration 29

Assessment by Molecule Type 31

Drug Profiles 33

anthrax + plague vaccine-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

ARD-3100-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

ciprofloxacin hydrochloride-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

plague vaccine-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

plague vaccine-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

plague vaccine-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

plague vaccine-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

plague vaccine-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

plague vaccine-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

plague vaccine-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

plague vaccine-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

plague vaccine-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

pneumonic plaque vaccine-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Small Molecules to Inhibit Yoph Protein Tyrosine Phosphatase for Plague-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

TP-271-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

Yersinia pestis vaccine-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

Plague-Recent Pipeline Updates 52

Plague-Dormant Projects 55

Plague-Discontinued Products 56

Plague-Product Development Milestones 57

Featured News & Press Releases 57

Mar 30, 2015: iBio European Plague Vaccine Patent Emerges From Opposition Period 57

Nov 19, 2012: UK Scientists Report On Efficacy Of Aradigm's Lipoquin Against Pneumonic Plague 57

Jun 05, 2008: Computer Sciences Corporation's DynPort Vaccine Company To Continue Plague Vaccine Development 59

Nov 18, 2005: Computer Sciences Corporation's DynPort Vaccine Company Reaches Milestone In Plague Vaccine Clinical Trial 59

May 17, 2005: Wake Forest Scientists Find New Combination Vaccine Effective Against Plague 59

Jan 10, 2005: Computer Sciences Corporation's DynPort Vaccine Company Enters Clinical Trial For Plague Vaccine Candidate 60

Appendix 61

Methodology 61

Coverage 61

Secondary Research 61

Primary Research 61

Expert Panel Validation 61

Contact Us 61

Disclaimer 62

List of Tables

Number of Products under Development for Plague, H2 2015 8

Number of Products under Development for Plague-Comparative Analysis, H2 2015 9

Number of Products under Development by Companies, H2 2015 10

Number of Products under Investigation by Universities/Institutes, H2 2015 11

Comparative Analysis by Clinical Stage Development, H2 2015 12

Comparative Analysis by Early Stage Development, H2 2015 13

Comparative Analysis by Unknown Stage Development, H2 2015 14

Products under Development by Companies, H2 2015 15

Products under Investigation by Universities/Institutes, H2 2015 16

Plague-Pipeline by Aradigm Corporation, H2 2015 17

Plague-Pipeline by Grifols, S.A., H2 2015 18

Plague-Pipeline by iBio, Inc., H2 2015 19

Plague-Pipeline by Mucosis B.V., H2 2015 20

Plague-Pipeline by Syntiron LLC, H2 2015 21

Plague-Pipeline by Tetraphase Pharmaceuticals Inc., H2 2015 22

Assessment by Monotherapy Products, H2 2015 23

Assessment by Combination Products, H2 2015 24

Number of Products by Stage and Target, H2 2015 26

Number of Products by Stage and Mechanism of Action, H2 2015 28

Number of Products by Stage and Route of Administration, H2 2015 30

Number of Products by Stage and Molecule Type, H2 2015 32

Plague Therapeutics-Recent Pipeline Updates, H2 2015 52

Plague-Dormant Projects, H2 2015 55

Plague-Discontinued Products, H2 2015 56

List of Figures

Number of Products under Development for Plague, H2 2015 8

Number of Products under Development for Plague-Comparative Analysis, H2 2015 9

Number of Products under Development by Companies, H2 2015 10

Number of Products under Investigation by Universities/Institutes, H2 2015 11

Comparative Analysis by Clinical Stage Development, H2 2015 12

Comparative Analysis by Early Stage Products, H2 2015 13

Assessment by Monotherapy Products, H2 2015 23

Number of Products by Top 10 Targets, H2 2015 25

Number of Products by Stage and Top 10 Targets, H2 2015 25

Number of Products by Top 10 Mechanism of Actions, H2 2015 27

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 27

Number of Products by Top 10 Routes of Administration, H2 2015 29

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 29

Number of Products by Top 10 Molecule Types, H2 2015 31

Number of Products by Stage and Top 10 Molecule Types, H2 2015 31

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Aradigm Corporation

Grifols, S.A.

iBio, Inc.

Mucosis B.V.

Syntiron LLC

Tetraphase Pharmaceuticals Inc.

Plague Therapeutic Products under Development, Key Players in Plague Therapeutics, Plague Pipeline Overview, Plague Pipeline, Plague Pipeline Assessment

select a license

Single User License
USD 2000 INR 129880
Site License
USD 4000 INR 259760
Corporate User License
USD 6000 INR 389640

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com